Diverting a Diet Drug

Diverting a Diet Drug How did a controversial product become the first weight-loss drug to be available without a prescription? By Fran Hawthorne Illustrations by Bill Sanderson Related Articles 1 "That was another big Aha! moment, because we didn't know that study existed," Burton says. The researchers found that people who took orlistat (the generic name for Xenical) experienced a 37% lower risk of type 2 diabetes. According to the report, "the overal

Written byBill Sanderson
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

By Fran Hawthorne
Illustrations by Bill Sanderson

1 "That was another big Aha! moment, because we didn't know that study existed," Burton says.

The researchers found that people who took orlistat (the generic name for Xenical) experienced a 37% lower risk of type 2 diabetes. According to the report, "the overall incidence of adverse events was similar" in the control group and the group on orlistat, although more people on orlistat experienced "mild to moderate" gastrointestinal events. (The incidence decreased as people stayed longer on the drug.) Along with the more common side effects, Xenical can interfere with the absorption of many drugs such as warfarin and cyclosporine, as well as fat-soluble vitamins. Rarely, it's been linked to acute kidney injury and liver problems. 2

The GSK team left the Marriott meeting eager to move ahead. But the ball was in Roche's court. And Roche wasn't sure it wanted to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies